The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
November 10, 2014
View Complete Issue         Table of Contents 2019 
Pembrolizumab (Keytruda) for Metastatic Melanoma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Pembrolizumab (Keytruda) for Metastatic Melanoma (online only)
November 10, 2014 (Issue: 1455)
The FDA has approved pembrolizumab (Keytruda – Merck), a human programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following treatment with ipilimumab (Yervoy) and, if...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Pembrolizumab (Keytruda) for Metastatic Melanoma (online only)
Article code: 1455e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.